Skip to main content

Fungizone Disease Interactions

There are 3 disease interactions with Fungizone (amphotericin b).

Moderate

Ampho B (applies to Fungizone) anemia

Moderate Potential Hazard, High plausibility.

Intravenous amphotericin B therapy may depress erythropoietin and red blood cell production and commonly causes a normocytic, normochromic anemia. Although the anemia is well tolerated by most patients and usually reverses completely within several months of stopping therapy, it may be problematic in patients with preexisting anemia. Intravenous therapy with amphotericin B should be administered cautiously in anemic patients or those predisposed to anemia. Frequent monitoring of blood counts and hemoglobin concentrations are recommended.

References

  1. Miller R, Bates J (1969) "Amphotericin B toxicity." Ann Intern Med, 71, p. 1089-95
  2. Maddux M, Barriere S (1980) "A review of complications of amphotericin B therapy: recommendations for prevention and management." Drug Intell Clin Pharm, 14, p. 177-81
  3. Struijk D, Krediet R, Boeschoten E, Rietra JG, Arisz L (1987) "Antifungal treatment of candida peritonitis in continuous ambulatory peritoneal dialysis patients." Am J Kidney Dis, 9, p. 66-70
  4. (1988) "Amphotericin." Med Lett Drugs Ther, 30, p. 30-2
  5. Lyman C, Walsh T (1992) "Systemically administered antifungal agents." Drugs, 44, p. 9-35
  6. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  7. (2022) "Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb
View all 7 references
Moderate

Amphotericin B (applies to Fungizone) electrolyte disturbances

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypocalcemia, Hypokalemia, Hyperkalemia, Magnesium Imbalance, Electrolyte Abnormalities

Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities. Mineral and electrolyte supplementation is frequently required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances. Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug's long terminal elimination half-life.

References

  1. Miller R, Bates J (1969) "Amphotericin B toxicity." Ann Intern Med, 71, p. 1089-95
  2. Patterson R, Ackerman G (1971) "Renal tubular acidosis due to amphotericin B nephrotoxicity." Arch Intern Med, 127, p. 241-4
  3. Maddux M, Barriere S (1980) "A review of complications of amphotericin B therapy: recommendations for prevention and management." Drug Intell Clin Pharm, 14, p. 177-81
  4. Barton C, Pahl M, Vaziri N, Cesario T (1984) "Renal magnesium wasting associated with amphotericin B therapy." Am J Med, 77, p. 471-4
  5. Arning M, Scharf R, Schneider W (1987) "Prevention of renal failure during long-term treatment with amphotericin-B." Klin Wochenschr, 65, p. 1108
  6. Branch R, Jackson E, Jacqz E, et al. (1987) "Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline." Klin Wochenschr, 65, p. 500-6
  7. (1988) "Amphotericin." Med Lett Drugs Ther, 30, p. 30-2
  8. Branch R (1988) "Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation." Arch Intern Med, 148, p. 2389-94
  9. Clements J, Peacock J (1990) "Amphotericin B revisited: reassessment of toxicity." Am J Med, 88, n22-7
  10. (2022) "Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb
View all 10 references
Moderate

Amphotericin B (applies to Fungizone) renal dysfunction

Moderate Potential Hazard, High plausibility.

Intravenously administered amphotericin B is nephrotoxic and may commonly cause decreased renal function and abnormalities including azotemia, hypo- and hyperkalemia, hypomagnesemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis. Renal function should be closely monitored in all patients receiving intravenous therapy with amphotericin B but in particular, patients with preexisting renal impairment. Dosage reductions are recommended. Serum creatinine, BUN, potassium and magnesium levels should be evaluated frequently, and dosing adjusted or discontinued accordingly.

References

  1. McCurdy D, Frederic M, Elkinton JR (1968) "Renal tubular acidosis due to amphotericin B." N Engl J Med, 268, p. 124-31
  2. Patterson R, Ackerman G (1971) "Renal tubular acidosis due to amphotericin B nephrotoxicity." Arch Intern Med, 127, p. 241-4
  3. Rosch J, Pazin G, Fireman P (1976) "Reduction of amphotericin B nephrotoxicity with mannitol." JAMA, 235, p. 1995-6
  4. Bullock W, Luke R, Nuttall C, Bhathena D (1976) "Can mannitol reduce amphotericin B nephrotoxicity?" Antimicrob Agents Chemother, 10, p. 555-63
  5. Barton C, Pahl M, Vaziri N, Cesario T (1984) "Renal magnesium wasting associated with amphotericin B therapy." Am J Med, 77, p. 471-4
  6. Arning M, Scharf R, Schneider W (1987) "Prevention of renal failure during long-term treatment with amphotericin-B." Klin Wochenschr, 65, p. 1108
  7. Branch R, Jackson E, Jacqz E, et al. (1987) "Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline." Klin Wochenschr, 65, p. 500-6
  8. Sacks P, Fellner S (1987) "Recurrent reversible acute renal failure from amphotericin." Arch Intern Med, 147, p. 593-5
  9. (1988) "Amphotericin." Med Lett Drugs Ther, 30, p. 30-2
  10. Branch R (1988) "Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation." Arch Intern Med, 148, p. 2389-94
  11. Fisher MA, Talbot GH Maislin G, McKeon BP, Tynan KP, Strom BL (1989) "Risk factors for amphotericin B-associated nephrotoxicity." Am J Med, 87, p. 547-52
  12. Clements J, Peacock J (1990) "Amphotericin B revisited: reassessment of toxicity." Am J Med, 88, n22-7
  13. Morgan DJ, Ching MS, Raymond K, et al. (1983) "Elimination of amphotericin B in impaired renal function." Clin Pharmacol Ther, 34, p. 248-53
  14. Chabot GG, Pazdur R, Valeriote FA, Baker LH (1989) "Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients." J Pharm Sci, 78, p. 307-10
  15. Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y (1993) "Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update." Perit Dial Int, 13, p. 14-28
  16. (2022) "Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb
View all 16 references

Fungizone drug interactions

There are 174 drug interactions with Fungizone (amphotericin b).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer